当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

CHAI:2021年HBV(乙型肝炎病毒)市场情报及HBV(丙型肝炎病毒)市场初步洞察报告(第二版)(中译版)(61页).pdf

上传人: Y**** 编号:164900 2023-06-13 61页 2.69MB

下载:

1、HCV Market Intelligence Report 2021 and Preliminary HBV Market Insights Clinton Health Access Initiative,Inc.(CHAI)2021Photography by:Soksamphoas Im,Christine McNab,Melinda StanleyDisclaimer:The data sources primarily used for analysis in the report include the India Import Export data,CHAI country

2、teams,Ministry of Health counterparts,stakeholder(WHO,MPP,and NGO and civil society partners,such as FIND,TAG,World Hepatitis Alliance,etc.)conversations,and regulatory information provided by drug suppliers.CHAI has taken precautions to verify the information shared on the report.However,the analys

3、is in the report is not exhaustive,and the responsibility for the interpretation and use of the material lies with the reader.The mention of specific companies or supplier products does not imply that CHAI is endorsing or recommending them.ContentsAcknowledgments.1Acronyms.2Executive summary.4Introd

4、uction.7COVID-19 impact and potential opportunities.7WHO-recommended HCV testing and treatment guidance updates .9HCV landscapes and trends.11HCV diagnostics.11Supplier landscape.12Pricing and cost considerations of screening and liver staging.14HCV viral load cost considerations .16HCV treatment.23

5、Supplier landscape.23Volume trends.25Pricing trends.27Retreatment market trends.30Pediatric HCV treatment.31Looking forward.33Preliminary information on the HBV market.35Introduction.35WHO-recommended HBV testing and treatment guidelines.36HBV diagnostic market trends.38HBV treatment market trends.4

6、0HBV birth dose vaccine market trends.41HBV markets on the horizon.41Glossary.42Appendix .43HCV Market Intelligence Report 2021 and Preliminary HBV Market Insights|1AcknowledgmentsThis publication was developed by the Clinton Health Access Initiative(CHAI).The shipment data obtained from the India i

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要概括了以下几个关键点: 1. 低成本、质量保证的诊断工具降低了低收入和中等收入国家(LMICs)有效诊断丙型肝炎病毒(HCV)的障碍。 2. 2020年,印度仿制药在LMICs的HCV直接作用抗病毒药物(DAA)市场达到约1600万美元。 3. 预计世界卫生组织(WHO)指南的修订将扩大市场,推荐泛基因型DAA用于青少年和儿童的HCV治疗。 4. 大多数世界卫生组织推荐的DAA方案现在至少有一个世界卫生组织预认证(PQ)的产品。 5. DAA价格下降放缓,下一次治疗成本的主要下降可能由供应链优化和各国集中采购推动。 6. 随着各国继续适应COVID-19的情况,丙型肝炎社区需要继续努力使HCV诊断和治疗更加可及。
低成本HCV诊断在LMICs中的作用是什么? 印度仿制药在HCV治疗市场中的地位如何? 新冠疫情对HCV诊断和治疗市场有何影响?
客服
商务合作
小程序
服务号
折叠